- Home
- TLPH vs PMCB Comparison
TLPH vs PMCB Comparison
Compare TLPH & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- PMCB
- Stock Information
- Founded
- TLPH 2005
- PMCB 1996
- Country
- TLPH United States
- PMCB United States
- Employees
- TLPH N/A
- PMCB N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLPH Health Care
- PMCB Health Care
- Exchange
- TLPH Nasdaq
- PMCB Nasdaq
- Market Cap
- TLPH 12.7M
- PMCB 11.4M
- IPO Year
- TLPH 2011
- PMCB N/A
- Fundamental
- Price
- TLPH $0.64
- PMCB $1.64
- Analyst Decision
- TLPH Strong Buy
- PMCB
- Analyst Count
- TLPH 2
- PMCB 0
- Target Price
- TLPH $4.50
- PMCB N/A
- AVG Volume (30 Days)
- TLPH 96.2K
- PMCB 14.2K
- Earning Date
- TLPH 11-13-2024
- PMCB 12-31-2024
- Dividend Yield
- TLPH N/A
- PMCB N/A
- EPS Growth
- TLPH N/A
- PMCB N/A
- EPS
- TLPH N/A
- PMCB 0.74
- Revenue
- TLPH $281,000.00
- PMCB N/A
- Revenue This Year
- TLPH N/A
- PMCB N/A
- Revenue Next Year
- TLPH N/A
- PMCB N/A
- P/E Ratio
- TLPH N/A
- PMCB $2.21
- Revenue Growth
- TLPH N/A
- PMCB N/A
- 52 Week Low
- TLPH $0.60
- PMCB $1.39
- 52 Week High
- TLPH $1.61
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- TLPH 39.75
- PMCB 45.24
- Support Level
- TLPH $0.60
- PMCB $1.60
- Resistance Level
- TLPH $0.76
- PMCB $1.69
- Average True Range (ATR)
- TLPH 0.07
- PMCB 0.11
- MACD
- TLPH -0.00
- PMCB -0.00
- Stochastic Oscillator
- TLPH 17.65
- PMCB 40.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.